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Figure 1. Response of four detectors in small fields, defined 
via the Alfonso k correction factor as the dose-to-water to 
dose-to-detector ratio in a small field divided by the same 
ratio in a reference (3×3 cm2) field, plotted for: (a) the 
whole detector vs a point of water; (b) whole detector vs a 
water voxel of the same size as the detector sensitive 
volume; (c) sensitive volume alone versus water voxel of the 
same size; (d) sensitive volume with density adjusted to that 
of water vs water voxel of the same size.      
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Densely ionizing radiation deposits the energy by 
electromagnetic or nuclear interactions along the tracks. This 
non-uniform energy deposition patterns generates a high 
number of clustered DNA lesions, which are difficult to 
repair. Therefore, protons, alpha particles, and heavy ions 
are generally more effective than X-rays in inducing 
biological damage.  For many years, particle therapy 
radiobiology concentrated on measurements of the relative 
biological effectiveness (RBE) of the energetic particles for 
tumour cell killing, generally using in vitro cell cultures 
exposed in monolayers at high-energy particle accelerators, 
such as the BEVALAC (Berkeley, USA), HIMAC (Chiba, Japan), 
and GSI (Darmstadt, Germany). The RBE-LET relationship is 
well known, and the large variability reflects the variance of 
the RBE, which is dependent upon many physical, chemical, 
and biological parameters.  More recently, it has been shown 
that densely ionizing radiation elicits signaling pathways 
quite distinct from those involved in the cell and tissue 
response to photons. The response of the microenvironment 
to charged particles is therefore under scrutiny, and both the 
damage in the target and non-target tissues are relevant. 
Hypofractionation, combined treatment modalities, and 
dose/LET painting are now under study in several accelerator 
facilities for clinical translation. Particle radiobiology is 
therefore now entering into a new phase, where beyond RBE 
the tissue response is considered. These results may open 
new applications in cancer therapy with charged particles 
(hadrontherapy). 
Teaching Lecture: Introduction to proton therapy 
SP-0352   
Introduction to proton therapy  
H. Nyström1 
1The Skandion Clinic, Uppsala, Sweden 
Proton therapy makes it possible to treat cancer more 
effectively and with fewer side effects than is often the case 
with conventional radiotherapy. With proton therapy, the risk 
of damage to healthy tissues can be brought to a minimum 
for a number of clinical indications. These attractive 
properties have led to a rapid expansion of the proton 
treatment capacity worldwide. As a matter of fact, the 
number of proton facilities is increasing exponentially and 
proton therapy will soon be widely available and not merely 
an exotic option only for a few highly specialised centres. For 
this reason, there is a need for a broader understanding of 
proton therapy, its potentials, but also its limitations and 
potential pitfalls. 
Proton therapy is often claimed to be “more precise” than 
conventional radiotherapy. This is because the dose 
distribution can be modulated also in the depth direction, 
contrary to IMRT where the depth dose distribution is more or 
less invariant with the modulation. This possibility does not, 
however, necessarily significantly improve the conformity of 
the high dose volume since e.g. the penumbra in many cases 
are worse than what can be achieved with photons. The rapid 
dose fall-off at the end of the proton track can be used to 
obtain sharp dose gradients and hence a highly tailored dose 
distribution, but unfortunately, due to uncertainties in the 
estimated range of the proton beam, this property is not 
possible to explore to its full potential. The fundamental and 
remaining advantage with proton therapy is hence the 
significant reduction to non-target tissues and a reduction in 
side effects. 
For most of the large groups of cancer patients, the highest 
level of evidence for the superiority of proton treatment over 
conventional radiotherapy is still lacking. There is an ongoing 
discussion about the potential ethical dilemma of 
randomising patients between standard radiotherapy and 
proton therapy which is “known” to be better. However, a 
large number of clinical trials are designed and the 
knowledge regarding the best use of proton therapy will 
increase over the coming years. What can be assumed with a 
reasonable high degree of evidence is that proton therapy, 
correctly applied, will decrease late toxicity and since less 
dose is deposited in non-target tissues, the risk of developing 
a new, radiation-induced cancer later in life is significantly 
reduced. This is of particular importance in paediatric 
patients. 
